Efficacy of different immunotherapy approaches toward treatment of doxorubicin-resistant and doxorubicin-sensitive transplantable rhabdomyosarcoma.
To evaluate the efficacy of different variants of immunotherapy, namely, adoptive LAK-therapy, vaccine therapy and their combination in vivo using transplantable murine MC-rhabdomyosarcoma resistant and sensitive to doxorubicin (Dox). The study was carried out on BALB/c mice bearing Dox-sensitive and Dox-resistant transplantable murine MC-rhabdomyosarcoma. LAK-therapy (using lymphocytes from lymph nodes of syngenic mice) was performed starting from day 7 after tumor cell transplantation for 5 days; LAK (3 x 10(6) cells in 0.2 ml medium) were injected in the region of tumor. The vaccine prepared on the base of tumor cell glycopeptides was administered intraperitoneally at the volume of 0.2 ml before or after tumor transplantation. Efficacy of immunotherapy was evaluated by tumor growth inhibition and life span of animals. By the indexes of tumor growth inhibition and average life span, for animals bearing Dox-sensitive tumors vaccine therapy was the most effective, whilst adoptive LAK-therapy was the most effective for mice bearing Dox-resistant tumors. All applied variants of therapy - adoptive LAK-therapy, vaccine therapy and their combination were effective for treatment of mice bearing Dox-sensitive and Dox-resistant transplantable murine MC-rhabdomyosarcoma. The obtained data demonstrated that Dox-sensitive and Dox-resistant tumors differ by the sensitivity to different types of immunotherapy.